PharmaEngine (4162) — Cash Flow Quality Index
PharmaEngine (4162) has a Cash Flow Quality Index of 0.39x as of September 2025. Operating cash flow of NT$53.01 Million is below net income of NT$136.46 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore PharmaEngine cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
PharmaEngine Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for PharmaEngine across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check cash flow reinvestment rate of PharmaEngine to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for PharmaEngine (2011–2024)
Year-by-year earnings quality comparison for PharmaEngine. For live market cap and the full company financial profile, see 4162 market cap overview.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.26x | NT$456.73 Million | NT$1.75 Billion | ▼ -72.1% |
| 2023 | 0.94x | NT$256.97 Million | NT$274.65 Million | ▲ +81.8% |
| 2022 | 0.51x | NT$202.01 Million | NT$392.46 Million | ▼ -69.8% |
| 2021 | 1.70x | NT$929.67 Million | NT$545.39 Million | ▲ +1880.4% |
| 2020 | 0.09x | NT$64.77 Million | NT$752.48 Million | ▼ -73.4% |
| 2019 | 0.32x | NT$16.08 Million | NT$49.67 Million | ▼ -92.9% |
| 2018 | 4.55x | NT$745.23 Million | NT$163.77 Million | ▲ +766.5% |
| 2017 | -0.68x | NT$-339.30 Million | NT$496.99 Million | ▼ -165.7% |
| 2016 | 1.04x | NT$870.38 Million | NT$837.91 Million | ▼ -5.6% |
| 2015 | 1.10x | NT$447.99 Million | NT$406.99 Million | ▲ +4.4% |
| 2014 | 1.05x | NT$131.09 Million | NT$124.32 Million | ▼ -24.8% |
| 2012 | 1.40x | NT$68.64 Million | NT$48.99 Million | ▲ +45.3% |
| 2011 | 0.96x | NT$275.49 Million | NT$285.71 Million | — |